Health
STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
Publication: STAT
Author: Adam Feuerstein
Source published: 01/10/2026, 10:30:00 UTC
Briefing created: 02/10/2026, 02:08:49 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 01/10/2026, 22:22:24 UTC.
Briefings
A Huntington's disease advocate named Lauren Holder was interviewed regarding UniQure's AMT-130 gene therapy, which slowed disease progression by 44% over a four-year period in 12 patients. The therapy's effect appears to have waned between the third and fourth year, prompting external questions about its long-term durability despite the company's positive claims.
Key points
- Lauren Holder, an advocate for Huntington's disease, was interviewed about UniQure's AMT-130 gene therapy.
- AMT-130 slowed Huntington's progression by 44% over a four-year period in 12 treated patients.
Context and limitations
The evidence is limited to a single interview with an advocate and does not include clinical trial data, patient outcomes, or long-term follow-up results.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 02/10/2026, 02:08:49 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeicsc3nytxafrqmwil5gjhceklzysf32eb6n3a5qud4gpkaa3qia2m